EXHIBIT 14
Case 2:03-cv-01729-RCB Document 83-15 FiIed10/31/2005 Page10f4
ARIRONA DEPARTMENT OF CORRFQTEONS
Continuous Progress Record (S.O.A.P.) R
DME ME ""S“E°%"?§.XYL¥‘e2E&’i$%,?l%‘駧€$T"STAFF P
P. ` _ l ,
NMIB 3/ u rv; me ' */ IFEQ
~ » » AM M s WMM M r/-< MM-
.\ viii " A lll ·— l ` I M
''`' inn!} » I/‘-#6*Ci 0/ ’A " m Q5
R A Q" 5 A A - 1wv-c(_,‘Z7·1/l
REED]! No ·· » { ,WM~»—=··M%m»
IQK-H-» cw · www .4 ,»·»-~€—s so
P`- iRRRR PR PPPRPRRRR RP` RP `RRP ` ¢ ,§q§€E 8 2¤ ¤5Q \ · j so
Ilgléilgg a - .. ., A L
l; . ee u P nnéeee
so nnPR uejoueus
P 6 Q uno -
' ;; -`V— ,`‘_ . _ »_‘: ‘—:4 > M ___,__ W ‘‘’‘ ‘ `*‘ _~__, A A,_~ M M,,w»~*"( A DEA BA608602 -_ i
== P Sp P
#1/ - so ,..u. .V»ee ’ ```‘ ·· N ' fx eg
-1. - _ `»o‘‘ ~ ¤ · .
5 lo 0 u
-
R BABOBBOZO-105
n- A r 7, M . .A» :,w .,
Z-- ¢...a..al
{" L/\r`( gNamg(La$g_F;r$gM_1_) v ADCNUFHPBV
CONTINUOUSPROGRESSRECORDUMM `· ' ;€ e \O OO`
M P m
Case 2:03-cv-01729-RCB Document 8 ’*& =’·-: 2 . **%-5 *2:- a = mm
mg'}
EXHIBIT 15 1
1
1
Case 2:03-cv-01729-RCB Document 83-15 Filed 10/31/2005 Page 3 014 1
Laboratory Corporation of America
ms1EiMEN TYPE (1>R1MARY LAB Q Rrrom STATUS; =
A 153-227-22280-0 s PD COMPLETE g Page#: 1 j
_ ( CLINICAL INFORMATIONR if iiiii 1
mO29.8.m.H-O08 2437 9 *‘A“““°·N DOBZ 2,2./19.3 _.oo be ac S
1 MARTINEZ,FELIPE M 40 / 3 %———-———--4—-—..»—-W A . A 3
‘PTpA5b;‘rrrrr"r·*—·r·——————~~*———————————#———————————~————; iACCOUNTE ASPC-LEWHS
— ----.-.—.»—— * ( 26700 s. Hwy 85
;DATEorsrtcHGER·_dmRE—VDXTEREEERHEYFBX¥ERE$5RTE5_*;iGE—V—_—w 1 BUCKEYE AZ 8iH60Om® _
6/02/2003 0;00 , 6/03/2003 * 6/07/2003 14:08 3135 I (Accoum NUMBER: 02256542
. ,._. .. _0,. A.00 ,i____l`E§LL RESULT . . LHVHI§--i__Lé§.,... L.
DRUG ABUSE, (7 DRUGS/ALCOHOL) I
. (ng/mL)’ TV
SCREEN CONFIR
DRUG RESULT CUTOFF CUTOFF
Amphetamines Negative 1000 TV
Barbiturate Negative 300.·· TV
Benzodiazepines 5 Negative 300 TV ~
Cannabinoid Negative 50 TV
Cocaine (Metab.) Negative 300 TV
Opiates Negative 300 TV
Phencyclidine Negative 25 TV
Ethanol U, Quan Negative Cutoff=0.020 TV
Alb+A1P+ALT+AST+Prot+TBili
Protein, Total, Serum 8.1 q/dL 6.0 — 8.5 PD 3
Albumin, Serum 4.5 » q/dL 3.5 — 5.5 PD
Globulin, Total 3.6 g/dL 1.5 — 4.5
A/G Ratio 1.3 1.1 — 2.5
Bilirubin, Total 1.2 mg/dL 0.1 — 1.2 PD
Alkaline Phosphatase, Serum 75 IU/L 25 — 150 PD_v“w%wN
> ‘â€"?4§·?T§6T> 42 H IU/L 3 0 — 40 ggzmig
> ALT (SGPT) 66 H IU/L O — 40 PD_______g____;
HEPATITIS c VIRUS GENOTYPING
Hepatitis C Genotype la A See Note TG
This assay can detect the six (6) major HCV Genotypes and
their most common subtypes.
Several clinical studies have demonstrated that Genotype 1
HCV may be more refractory to interferon monotherapy as
well as to interferon plus ribavirin combination therapy. _
Sustained response rates are increased for Genotype 1 ·
infected patients when therapy is given for 48 weeks ,
instead of 24 weeks. `
. /4/A3
_ A Q; TG
. HONOLFO MACABUHAY MD
This test was developed and its performance character- DEA BA608602[)-105
istics determined by LabCorp. It has not been cleared -
or approved by the U.S. Food and Drug Administration.
Results are Flagged in Accordance with Age Dependent Reference Ranges A
Continued on Next Page
Case 2:03-cv-01729-RCB Document 83-15 Filed 10/31/2005 L Page 4 014 ~ \0q
Case 2:03-cv-01729-RCB
Document 83-15
Filed 10/31/2005
Page 1 of 4
Case 2:03-cv-01729-RCB
Document 83-15
Filed 10/31/2005
Page 2 of 4
Case 2:03-cv-01729-RCB
Document 83-15
Filed 10/31/2005
Page 3 of 4
Case 2:03-cv-01729-RCB
Document 83-15
Filed 10/31/2005
Page 4 of 4